Anton Health’s Post

🎉 Exciting News: for Diabetic patients #Evapharma Introducing Mellitofix TRIO, a groundbreaking pharmaceutical innovation designed to revolutionize healthcare. Backed by years of rigorous research and development trials, MELLITOFIX TRIO promises to redefine #diabetestreatment standards, offering hope to millions worldwide. Learn more about this transformative advancement in medicine! BY asking your physician #HealthcareInnovation #BreakthroughTreatment #evapharma #diabetes

🎧 New Episode Alert! 🌟 Join hosts Bradley Nelson & Tom Davis on Pharmland as they delve into biosimilars. Discover why these alternatives to specialty drugs are slow to catch, their cost-saving potential, and more. Don’t miss this insightful discussion! 🌿 Listen now: https://rxbene.fit/3S7XWH2 #EmployeeBenefits #Pharmacy #PharmacyBenefits #DrugCosts #DrugPricing #Selffunded #PBO #PBM #RxBenefits #PharmlandPodcast #Biosimilars #PharmacyManagement

Pharmacists, don't miss out on Liebherr Professional Appliances at the Clinical Pharmacy Congress, ExCeL London, 10-11 May. Explore our pharmaceutical appliances & special deal on SmartMonitoring. Meet Mohammed Choudhury for insights! #CPCongress #PharmaTech #ExCeL #LiebherrAppliances

Missed the CCI webinar on pain, coughs and colds?🤔 No problem. Watch the recording and download the presentations here: https://bit.ly/3S44Gpw #CCIWebinarSeries #SAHPRA #StakeholderEngagement

The FDA recently approved the 10th Humira biosimilar. Why is this one different? --- Alvotech and Teva Pharmaceuticals recently announced the approval of their Humira biosimilar Simlandi (in the comments). There are already 9 other #biosimilars on the market, so why is this one special? --- Simlandi has a few characteristics that make it a unique Humira biosimilar: - It's citrate free - It's high concentration - It has interchangeable status --- Why are each of these important? -Citrate is a buffer that stabilizes medications, but it can also cause burning at the injection site. Patients typically prefer the citrate-free versions. -The high concentration means there's less volume to inject, which again makes it easier/more comfortable for the patient. In addition, ~85% of Humira market share is the high concentration version, so we already know that's what patients prefer and doctors write. -Interchangeable status allows pharmacists to dispense the biosimilar version without asking the doctor, even if the doctor wrote "Humira" on the prescription. The other biosimilars are still bioequivalent, but the interchangeable status makes the shift to the biosimilar operationally easier for everyone. --- The big differentiator for Simlandi is that it has all three characteristics, particularly the high concentration + interchangeable status. Both of the other interchangeable biosimilars (Abrilada and Cyltezo) are only available as low-concentration versions. And as mentioned above, ~85% of market share is the high-concentration version. --- None of this means Simlandi will be the biosimilar that "wins" and gets most of the #MarketShare, but it does currently have a competitive advantage. The biggest question now is...what's the price?? Still no word on the #DrugPricing or rebate games...which are arguably more important than everything I said above.

Can we avoid repeating past mistakes with biosimilars? As more #biosimilars enter the market, high barriers – from formulary delays to rebate structures – are slowing their adoption. In his latest article for Pharmacy Times, Chief Pharmacy Officer Mark Campbell, PharmD, explains why the launch of Humira biosimilars fell short of expectations and how we can seize new opportunities as biosimilars for Stelara and other costly medications come to market. Read more on how overcoming these challenges could transform pharmacy costs and access: https://ow.ly/61yZ50TUUiT #PharmacyBenefits #HealthcareCosts #Biosimilars #RxBenefits

Thoughts on this? >> Sandoz wins FDA approval for first two biosimilars for Amgen's blockbuster bone drug >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #productmarketing #pharma #healthcare

Thoughts on this? >> Sandoz wins FDA approval for first two biosimilars for Amgen's blockbuster bone drug >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #pharma #productmarketing #healthcare

Polaris Specialty Pharmacy is now part of the Specialty Pharmacy Network for TYMLOS. Polaris Specialty Pharmacy has partnered with Radius Health, a global biopharmaceutical company focused on addressing unmet medical needs in the area of bone health. Check out www.radiuspharm.com TYMLOS is for the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy. The treatment to increase bone density in men with osteoporosis at high risk for fracture (defined as a history of osteoporotic fracture or multiple risk factors for fracture), or patients who have failed or are intolerant to other available osteoporosis therapy. #specialtypharmacy #pharmacy #pharmaceuticalindustry #marketaccess #biopharmaceutical #pharma #lifesciences Polaris Specialty Pharmacy Polaris Pharmacy Services National Association of Specialty Pharmacy (NASP) Pharmacy Podcast Network Sol Carro Díaz Raquel D. Doug Albers David Rombro

The industry is still "buzzing" about new biosimilars and their impact on both members and plans. In our latest Fast Five, we explore biosimilar pricing and the incentives motivating drug manufacturers and pharmacy benefit managers (PBMs). Read the full article here: https://lnkd.in/gCGgkj_k #biosimilars #epiphanyrx #pbm #formularymanagement #pharmacybenefits #humira